| Home | Back To Index |

Comprehensive Analysis of R&D and Commercialization for
Related Biotechnologies from
Non-Biotechnology/Non-Pharmaceutical Companies 100
Price: English or Japanese Version $998 (Hardcopy)
English or Japanese Version $1,495 (PDF Department License)
Published: February 22, 2007
Total Page: 200 pages

Research Objectives


This Fuji-Keizai USA report explores research and development activities, business operations, investments and overall policies on biotechnology from the non-pharmaceutical, non-biotech company perspective. The organizations included in this report were selected because their core business is outside pure-play biotechnology and pharmaceutical drug development. The purpose is to understand to what extent, and why, industries such as IT, chemical companies, electronics giants, energy companies, among others, have an interest in biotechnology.

Target Companies
We start with a big picture of 100 non-pharma, non-biotech organizations. The organizations are predominantly U.S. Fortune 500 and European Fortune Global 500 businesses, as well as top U.S. hospitals and educational institutions. Next, we look at a piece of that organization - the divisional picture - and describe the business unit or other internal group, often within R&D, that is advancing biotechnology, either through commercialization of a product, internal research and/or a strategy of partnerships or acquisition. Our sources were publicly available data and phone interviews. Because the organizations come from different industrial sectors, their uses for biotechnology range from medicine, to consumer products such as clothing and food, to biofuel production. One of more biotechnology-related projects at each of the companies is described.

Biotechnology Defined
Biotechnology is synonymous with genomics (the study of genes) and proteomics (the study of proteins), where molecular biology and information technology are the tools used by scientists to develop advanced drugs. Because our scope is beyond pharmaceutical biotech alone, we have broadened the definition of biotechnology for this report to mean any technology where biological substances (e.g., human cells, tissue, plants, microorganisms, enzymes, etc.) are converted into a marketable product, system or process for medical or/and industrial application.

Overview of R&D Trends

1. Development of drugs or therapies to improve human health is still a primary focus of biotechnology research being done outside of the pharmaceuticals industry.
2. Commercialization of biotechnologies as applied to industrial processes is the next wave.
3. Fortune 500 companies have or are refashioning their role in the biotech universe in the face of marketplace realities.
4. Major consumer-oriented companies are showing a willingness to get involved in a new generation of biotech food research.

Targeted Segments of Companies
  Non-Biotechnology/Non-Pharmaceutical Companies # of Companies/Organizations
1 Food (consumer food/beverage & food/feed production)17
2 Chemicals 12
3 IT (computer HW/SW, semiconductors)10
4 Healthcare/hospitals/ Medical devices, equipment 10
5 Education/academia12
6 Personal care / household products, Aerospace, Energy,
Electronics equipment, Automotives, Paper, packaging,
Metals, Farm equipment, Waste management, Retail
39
Total  100


Targeted Companies 100
3M, Adidas, ADM, AES, Alcoa, Apple Computer, Arizona State University, BASF, Bausch & Lomb, Baxter, Becton Dickinson, Boston Scientific, Bunge, Cargill, Carl Zeiss, Chevron, Ciba, Coca-Cola, Cleveland Clinic, Colgate-Palmolive, ConAgra Foods, Coors, Cornell University, DSM, DTE Energy, Corning, DaimlerChrysler, Danisco, Degussa, Dole Food, Dow Chemical, DUPont, Eastman Chemical, Ford Motor, GE, General Dynamics, General Mills, General MotorsGeorgia-Pacific, Goodyear, Group Danone, Harvard, H.B. Fuller, Hewlett-Packard, Honeywell,IBM, Intel, International Paper, John Deere, Johns Hopkins, Johnson & Johnson, Kellogg, Kensey Nash, Kimberly-Clark, Kodak, Kraft Foods, Land O' Lakes, Lockheed Martin, Mayo Clinic, M.D. Anderson Cancer Center, MeadWestvaco, Medtronic, Microsoft, MIT, Monsanto,Motorola, Nestle, Northrop Grumman, Northwestern University, Philips, Procter & Gamble,Purdue University, Raytheon, Rockwell Automation, Rohm and Haas, Royal Dutch/Shell,Siemens, St. Louis University, Stanford University, STMicroelectronics, Stryker, Tate & Lyle,Sun Microsystems, Texas Instruments, UC-Berkeley, UC-Davis, Unilever, United Devices, University of Pennsylvania, UPMC Health System, United Technologies, Volvo, Weyerhaeuser, WMI, Wal-Mart, Welch's, W.R. Grace, Xerox


Table of Contents

1. Overview if R&D Trends and Directions
2. R&D Trends by Companies
   2.1 Percent (%) Share by Company Type (Breakdown)
   2.2 Percent (%) Share by Target R&D Segment
   2.3 Share by Target R&D Segment, by Company Type
   2.4 Other Analysis Based on Individual Companyfs Activity
   2.5 Market Size and R&D

3. Case Studies of 100 Companies
Common Research Item
   1) Company Name and Contact Information
   2) Biotechnology Division Name and Contact Information
   3) Divisionfs Function within Organization (Why does the company need this kind of
       Division? Why does it invest in this area of biotech development?)
   4) Division Information (# of staff, budget, etc)
   5) R&D description (technology, application, etc)
   6) Technology or/and Application Competitive Advantages
   7) Strategic Alliances
   8) Business Segment: Market size Forecast



FOR ORDER OR INQUIRY, PLEASE CLICK "ORDER / INQUIRY FORM"